Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Completed
Alcon Research
Phase 3
2006-04-18
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in
the treatment of the signs and symptoms associated with allergic conjunctivitis or
rhinoconjunctivitis.
The purpose of this study is to determine whether olopatadine nasal spray is safe and
effective when used for up to one year by patients with perennial allergic rhinitis.
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
Completed
Alcon Research
Phase 3
2007-09-01
A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal
spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6
to 11 years with a history of seasonal allergic rhinitis.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
